Jon Edelson, MD, is the Chairman, CEO, and President of Eirion Therapeutics
What’s Next for ET-02? CEO of Eirion, Jon Edelson, MD, Shares Phase 2 Plans
“As good as we saw results in 1 month, we think we'll see even more remarkable results over the 6 months of treatment,” Edelson said in an interview with Dermatology Times.
The Unprecedented Phase 1 Results of ET-02 for the Treatment of Androgenic Alopecia
Jon Edelson, MD, CEO of Eirion, confirms that topical ET-02 is a completely new approach to treating this type of hair loss.
Daily Derm Times: April 18, 2025
Treating Rosacea and Other Concerns with Generative Skin’s Ingredient Library
The Hidden Complexity of Reporting AEs
Immunocompromised Patients with Actinic Keratosis Respond Well to LED Daylight Photodynamic Combination Therapy